Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: KínaFázis nélkül

The Value of LC-MS/MS Detection of Androgen Profiles in the Diagnosis of PCOS: A Prospective, Multicenter Real-world Study

A legfontosabb adatok

Ki végzi
Women's Hospital School Of Medicine Zhejiang University
Hol
Hangzhou (Kína)A helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
1500 fő, tervezett
Kezdés
2026. júl. 1.
Várható befejezés
2028. dec. 31.
A vizsgálat típusa
Megfigyeléses, 2 csoport
A vizsgált kezelések
  • No Intervention: Observational Cohort
A regiszteradat frissítve
2026. november 4.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for women with polycystic ovary syndrome (PCOS), and healthy women of similar age as a comparison group. It tests whether a precise blood test of male-type hormones (androgens) helps diagnose PCOS.

Életkor
18 Years to 40 Years
Nem
Women only
A betegség stádiuma
PCOS group: women with at least two of three features (rare or no ovulation, signs of high androgens, many small cysts on the ovaries on ultrasound). Control group: women with regular periods, no signs of high androgens and no cystic ovaries on ultrasound.
Korábbi kezelés
People who took medicines that affect hormone release in the 3 months before joining cannot join.

A részvétel fő kizáró okai

  • Ovarian resistance syndrome, complete androgen insensitivity syndrome or similar conditions
  • Functional hypothalamic amenorrhea (periods stopped due to brain hormone signals)
  • Adrenocortical hyperplasia (overactive adrenal glands)
  • Thyroid problems, high prolactin or other hormone disorders
  • Medicines affecting hormone release within 3 months before joining

A regiszter feltételei, szó szerint

Mind a 3 feltétel megnézéseKevesebb

Ki vehet részt

  • PCOS group:Women who meet the Rotterdam diagnostic criteria (at least two of the following three features after excluding other endocrine disorders: oligo-ovulation/anovulation, clinical and/or biochemical hyperandrogenism, and polycystic ovarian morphology on ultrasound)
  • Control group: Age-matched healthy women or women attending the clinic for routine gynecological check-ups who have regular menstrual cycles and show no clinical or biochemical signs of hyperandrogenism, and no polycystic ovarian morphology on ultrasound

Ki nem vehet részt

  • Ovarian resistance syndrome, complete androgen insensitivity syndrome, functional hypothalamic amenorrhea, adrenocortical hyperplasia, and other similar conditions; Use of medications that affect hormone secretion within 3 months prior to enrollment; Thyroid dysfunction, hyperprolactinemia, and other endocrine disorders.-

Nézd meg, megfelelhetsz-e

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 18 és 40 év között vagy?

Helyszínek itt: Kína

  • Women's hospital school of medicine Zhejiang UniversityHangzhou, KínaContact: Runju ZhangRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

Introduction : Androgens play a vital role in the female reproductive system, influencing ovarian follicular development, oocyte quality, and ovarian responsiveness to controlled ovarian stimulation. The main circulating androgens include dehydroepiandrosterone sulfate (DHEA-S), dehydroepiandrosterone (DHEA), androstenedione (AD), testosterone (T), and dihydrotestosterone (DHT). Studies have shown that androgens promote early follicular growth by regulating follicle-stimulating hormone (FSH) receptor expression and the intrafollicular microenvironment; however, excessive levels may interfere with follicular maturation and ovulation, leading to ovarian dysfunction. Total testosterone (TT) represents the sum of bound and free circulating testosterone. The majority of circulating testosterone is tightly bound to sex hormone-binding globulin (SHBG) or loosely bound to albumin (ALB), α-globulins, and corticosteroid-binding globulin, with only 1-4% existing as free testosterone (FT). Only free testosterone can enter cells and exert biological effects. Because SHBG concentrations are readily influenced by sex, age, body weight, metabolic syndrome, SHBG gene polymorphisms, and certain medications, whereas FT is unaffected by SHBG, FT is considered an ideal marker for assessing bioactive testosterone status. Free testosterone, as the most biologically active androgen form, is closely correlated with ovarian response, particularly in patients with polycystic ovary syndrome (PCOS).

A teljes eredeti leírásKevesebb

Mass spectrometry (LC-MS/MS)is widely recognized as a highly accurate method for determining androgen profiles. However, due to various factors such as cost, large-scale studies using mass spectrometry to measure androgen profiles have not yet been conducted, and there is even a lack of research on the diagnostic performance of mass spectrometry-derived androgen profiles for polycystic ovary syndrome (PCOS).

The aim of this study is to evaluate the diagnostic performance (AUC, sensitivity, and specificity) of LC-MS/MS-measured androgen profiles in a multicenter real-world cohort for PCOS diagnosis. We will compare the diagnostic value of DHEA-S, DHEA, AD, T, DHT, and FT, and develop a multi-marker combined diagnostic model using machine learning to optimize the diagnostic efficacy for PCOS.

The primary research question is: Can LC-MS/MS-measured androgen profiles improve the diagnostic accuracy for PCOS?

By recruiting an appropriate number of participants and measuring the above serum biomarkers, we will statistically analyze the diagnostic performance of LC-MS/MS-determined androgen profiles, especially free testosterone (FT), in PCOS.

A vizsgálat 2 csoportja

  • PCOS group according to the diagnostic criteria of Rotterdam criteria

    Kezelés: No Intervention: Observational Cohort

  • control group

    Kezelés: No Intervention: Observational Cohort

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Illeszkedési kérdések
Forrás: NCT07916909: ki vehet részt
A regiszteradat frissítve
2026. november 4.